News for hackers. Stuff that matters.
Re:A Government Guide to Keeping Insulin Unaffordable by rayiner on Sunday July 07, 2019 @07:36PM (#20378730)
“Evergreening” is a term made up by journalists that has no basis in patent law, and is also actively misleading.

The real issue is that nobody has an incentive to prescribe the older, less good but still acceptable drug. (In the case of insulin, note, it’s not only the delivery mechanisms that have improved, but the insulin itself.) the insurance company, in particular, under the ACA, have no incentive to cut costs to improve profits.

Re:A Government Guide to Keeping Insulin Unaffordable by pessimizer on Sunday July 07, 2019 @09:45PM (#20379306)
Or, in the case of albuterol inhalers, the companies can actively lobby to prevent the older version from being distributed anymore.

Evergreening is absolutely a thing, and absolutely planned and executed by the companies that profit from it.

Re:A Government Guide to Keeping Insulin Unaffordable by pg_bot on Sunday July 07, 2019 @11:21PM (#20379643)
The older albuterol inhalers are no longer sold because they used CFCs as a propellant. CFC usage was banned internationally by the Montreal protocol in 1987. The propellant could not be immediately replaced due to strict FDA safety guarantees so they carved out a temporary exemption for medical usage. Research and development was done to find a replacement (HFAs) and that work is now being paid for by the patents granted from that process (more expensive inhalers). Whether this was a valid trade-off is a separate discussion but company lobbying is not the reason why they are no longer distributed.

https://www.fda.gov/drugs/questions-answers/transition-cfc-p...

Re:A Government Guide to Keeping Insulin Unaffordable by tptacek on Monday July 08, 2019 @11:44AM (#20383687)
I think his point is that evergreening isn't a feature of the patent system; there's no mechanism to extend a patent, and "extension" patents of minor modifications don't extend the legal monopoly on a drug, but rather function as a marketing mechanism that preys on the industry's willingness to prescribe whatever the newest iteration of a drug is, regardless of evidence.
Re:A Government Guide to Keeping Insulin Unaffordable by drunkpotato on Sunday July 07, 2019 @11:50PM (#20379760)
I fail to see how the term "evergreening" is misleading. It seems to me to be an accurate term that precisely describes an industry practice responding to market and regulatory incentives. I think journalists are spot on for this one, "evergreening" is an accurate and completely truthful assessment of the situation, and perhaps you are thinking too narrowly within the scope of legal terms in patent law and not enough about real world effects.
Re:A Government Guide to Keeping Insulin Unaffordable by jablongo2 on Sunday July 07, 2019 @10:00PM (#20379357)
There may be some confusion about "delivery mechanism" here. In this context the only relevant definition would be referring to chemical components in updated formulas for the injectable solution. Delivery _devices_ would have no relevance to the patent of the injectable solution.
[dead]
Re:A Government Guide to Keeping Insulin Unaffordable by dang on Monday July 08, 2019 @02:51AM (#20380442)
This breaks the site guidelines badly. Personal attacks are not allowed here. Accusations of shilling are not allowed here. We ban accounts that do these things. Please read the rules and don't do them again.

https://news.ycombinator.com/newsguidelines.html